{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T22:40:10Z","timestamp":1792708810275,"version":"4.5.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T00:00:00Z","timestamp":1784937600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:00:00Z","timestamp":1792713600000},"content-version":"vor","delay-in-days":90,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Weekly paclitaxel combined with ramucirumab is the standard second-line chemotherapy regimen for advanced gastric cancer. Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) is increasingly used as it lowers the risk of hypersensitivity reactions; however, full-dose nab-paclitaxel (100\u00a0mg\/m\u00b2) combined with ramucirumab frequently leads to severe myelosuppression. In clinical practice, dose reduction is often required, particularly in older patients or those with a poor performance status. However, the clinical efficacy and safety of a reduced-dose regimen of nab-paclitaxel combined with ramucirumab have not yet been prospectively evaluated. Accordingly, this multicenter phase II study aimed to assess the efficacy and tolerability of reduced-dose nab-paclitaxel combined with ramucirumab as second-line treatment for advanced gastric cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This open-label, single-arm, multicenter phase II trial was conducted at nine institutions between March 2018 and August 2021 and enrolled 50 patients with unresectable or recurrent gastric or esophagogastric junction adenocarcinoma who had previously undergone treatment with fluoropyrimidine-based chemotherapy. Nab-paclitaxel (80\u00a0mg\/m\u00b2) was administered intravenously on days 1, 8, and 15 in combination with ramucirumab (8\u00a0mg\/kg) on days 1 and 15 of each 28-day cycle. The primary endpoint was progression-free survival. The secondary endpoints included overall survival, response rate, disease control rate, relative dose intensity, and safety. Tumor responses were assessed using the Response Evaluation Criteria in Solid Tumors v1.1.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The median progression-free survival was 5.8 months (95% confidence interval [CI], 4.6\u20137.0). The median overall survival was 12.5 months (95% CI, 10.6\u201314.5). Among patients with measurable lesions, the objective response rate was 33.3%, including one case of complete response. The disease control rate was 80%. Grade\u2009\u2265\u20093 neutropenia occurred in 50% of patients, whereas febrile neutropenia occurred in 2%. The relative dose intensity was 86.5% for nab-paclitaxel and 92.8% for ramucirumab.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Reduced-dose nab-paclitaxel combined with ramucirumab demonstrated modest efficacy and favorable tolerability as second-line chemotherapy for advanced gastric cancer. This regimen may represent a practical treatment alternative for patients deemed unsuitable for full-dose nab-paclitaxel due to concerns regarding its toxicity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>This study was registered in the UMIN Clinical Trials Registry on February 14, 2018 (UMIN000031285).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-026-16587-x","type":"journal-article","created":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T12:34:14Z","timestamp":1784982854000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Reduced-dose nanoparticle albumin-bound-paclitaxel combined with ramucirumab as second-line treatment for advanced gastric cancer: a multicenter phase II study"],"prefix":"10.1186","volume":"26","author":[{"given":"Michihisa","family":"Iida","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiyo","family":"Nakashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toru","family":"Kawaoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junya","family":"Kondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsunenori","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigefumi","family":"Yoshino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhisa","family":"Tokuno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Kuga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koji","family":"Dairaku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Nakagami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusaku","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroto","family":"Matsui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshitaro","family":"Shindo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidenori","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuya","family":"Ioka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Nagano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,25]]},"reference":[{"issue":"3","key":"16587_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin. 2024;74(3):229\u201363.","journal-title":"Cancer J Clin"},{"issue":"2","key":"16587_CR2","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/S1470-2045(21)00692-6","volume":"23","author":"YK Kang","year":"2022","unstructured":"Kang YK, Chen LT, Ryu MH, Oh DY, Oh SC, Chung HC, Lee KW, Omori T, Shitara K, Sakuramoto S, et al. Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2022;23(2):234\u201347.","journal-title":"Lancet Oncol"},{"issue":"11","key":"16587_CR3","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1016\/S1470-2045(23)00515-6","volume":"24","author":"SY Rha","year":"2023","unstructured":"Rha SY, Oh DY, Ya\u00f1ez P, Bai Y, Ryu MH, Lee J, Rivera F, Alves GV, Garrido M, Shiu KK, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2023;24(11):1181\u201395.","journal-title":"Lancet Oncol"},{"issue":"17","key":"16587_CR4","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1200\/JCO.23.01601","volume":"42","author":"YY Janjigian","year":"2024","unstructured":"Janjigian YY, Ajani JA, Moehler M, Shen L, Garrido M, Gallardo C, Wyrwicz L, Yamaguchi K, Cleary JM, Elimova E, et al. First-Line Nivolumab Plus Chemotherapy for Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: 3-Year Follow-Up of the Phase III CheckMate 649 Trial. J Clin oncology: official J Am Soc Clin Oncol. 2024;42(17):2012\u201320.","journal-title":"J Clin oncology: official J Am Soc Clin Oncol"},{"issue":"6","key":"16587_CR5","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1007\/s00280-018-3569-9","volume":"81","author":"S Iizumi","year":"2018","unstructured":"Iizumi S, Takashima A, Sakamaki K, Morita S, Boku N. Survival impact of post-progression chemotherapy in advanced gastric cancer: systematic review and meta-analysis. Cancer Chemother Pharmacol. 2018;81(6):981\u20139.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"3","key":"16587_CR6","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1007\/s10120-020-01067-3","volume":"23","author":"Y Hamamoto","year":"2020","unstructured":"Hamamoto Y, Piao Y, Makiyama A. Achieving sequential therapy in advanced gastric cancer: the importance of appropriate patient management for the elderly and\/or those with ascites. Gastric cancer: official J Int Gastric Cancer Association Japanese Gastric Cancer Association. 2020;23(3):363\u201372.","journal-title":"Gastric cancer: official J Int Gastric Cancer Association Japanese Gastric Cancer Association"},{"issue":"3","key":"16587_CR7","doi-asserted-by":"publisher","first-page":"e000206","DOI":"10.1136\/esmoopen-2017-000206","volume":"2","author":"M Salati","year":"2017","unstructured":"Salati M, Di Emidio K, Tarantino V, Cascinu S. Second-line treatments: moving towards an opportunity to improve survival in advanced gastric cancer? ESMO open. 2017;2(3):e000206.","journal-title":"ESMO open"},{"issue":"4","key":"16587_CR8","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1056\/NEJMoa2503119","volume":"393","author":"K Shitara","year":"2025","unstructured":"Shitara K, Van Cutsem E, G\u00fcm\u00fc\u015f M, Lonardi S, de la Fouchardi\u00e8re C, Coutzac C, Dekervel J, Hochhauser D, Shen L, Mansoor W, et al. Trastuzumab Deruxtecan or Ramucirumab plus Paclitaxel in Gastric Cancer. N Engl J Med. 2025;393(4):336\u201348.","journal-title":"N Engl J Med"},{"issue":"11","key":"16587_CR9","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1016\/S1470-2045(14)70420-6","volume":"15","author":"H Wilke","year":"2014","unstructured":"Wilke H, Muro K, Van Cutsem E, Oh SC, Bodoky G, Shimada Y, Hironaka S, Sugimoto N, Lipatov O, Kim TY, et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol. 2014;15(11):1224\u201335.","journal-title":"Lancet Oncol"},{"issue":"9","key":"16587_CR10","first-page":"2112","volume":"56","author":"A Sparreboom","year":"1996","unstructured":"Sparreboom A, van Tellingen O, Nooijen WJ, Beijnen JH. Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle Cremophor EL. Cancer Res. 1996;56(9):2112\u20135.","journal-title":"Cancer Res"},{"issue":"3","key":"16587_CR11","doi-asserted-by":"publisher","first-page":"165","DOI":"10.2165\/11634690-000000000-00000","volume":"12","author":"T Aomori","year":"2012","unstructured":"Aomori T, Makino H, Sekizuka M, Hashita T, Araki T, Iizuka K, Nakamura T, Yamamoto K. Effect of ethanol in Paclitaxel injections on the ethanol concentration in exhaled breath. Drugs R D. 2012;12(3):165\u201370.","journal-title":"Drugs R D"},{"issue":"13","key":"16587_CR12","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.1016\/S0959-8049(01)00171-X","volume":"37","author":"H Gelderblom","year":"2001","unstructured":"Gelderblom H, Verweij J, Nooter K, Sparreboom A. Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur J cancer (Oxford England: 1990). 2001;37(13):1590\u20138.","journal-title":"Eur J cancer (Oxford England: 1990)"},{"issue":"8","key":"16587_CR13","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1517\/14656566.7.8.1041","volume":"7","author":"WJ Gradishar","year":"2006","unstructured":"Gradishar WJ. Albumin-bound paclitaxel: a next-generation taxane. Expert Opin Pharmacother. 2006;7(8):1041\u201353.","journal-title":"Expert Opin Pharmacother"},{"issue":"18","key":"16587_CR14","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","volume":"369","author":"DD Von Hoff","year":"2013","unstructured":"Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, Seay T, Tjulandin SA, Ma WW, Saleh MN, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369(18):1691\u2013703.","journal-title":"N Engl J Med"},{"issue":"31","key":"16587_CR15","doi-asserted-by":"publisher","first-page":"7794","DOI":"10.1200\/JCO.2005.04.937","volume":"23","author":"WJ Gradishar","year":"2005","unstructured":"Gradishar WJ, Tjulandin S, Davidson N, Shaw H, Desai N, Bhar P, Hawkins M, O\u2019Shaughnessy J. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin oncology: official J Am Soc Clin Oncol. 2005;23(31):7794\u2013803.","journal-title":"J Clin oncology: official J Am Soc Clin Oncol"},{"issue":"17","key":"16587_CR16","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1200\/JCO.2011.39.5848","volume":"30","author":"MA Socinski","year":"2012","unstructured":"Socinski MA, Bondarenko I, Karaseva NA, Makhson AM, Vynnychenko I, Okamoto I, Hon JK, Hirsh V, Bhar P, Zhang H, et al. Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial. J Clin oncology: official J Am Soc Clin Oncol. 2012;30(17):2055\u201362.","journal-title":"J Clin oncology: official J Am Soc Clin Oncol"},{"key":"16587_CR17","doi-asserted-by":"crossref","unstructured":"Bando H, Shimodaira H, Fujitani K, Takashima A, Yamaguchi K, Nakayama N, Takahashi T, Oki E, Azuma M, Nishina T et al. A phase II study of nab-paclitaxel in combination with ramucirumab in patients with previously treated advanced gastric cancer. European journal of cancer (Oxford, England: 1990). 2018;91:86\u201391.","DOI":"10.1016\/j.ejca.2017.11.032"},{"issue":"1","key":"16587_CR18","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1007\/s12325-021-01931-3","volume":"39","author":"Y Komatsu","year":"2022","unstructured":"Komatsu Y, Hironaka S, Tanizawa Y, Cai Z, Piao Y, Boku N. Treatment Pattern for Advanced Gastric Cancer in Japan and Factors Associated with Sequential Treatment: A Retrospective Administrative Claims Database Study. Adv therapy. 2022;39(1):296\u2013313.","journal-title":"Adv therapy"},{"issue":"5","key":"16587_CR19","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1007\/s00280-019-03802-9","volume":"83","author":"K Nishikawa","year":"2019","unstructured":"Nishikawa K, Murotani K, Fujitani K, Inagaki H, Akamaru Y, Tokunaga S, Takagi M, Tamura S, Sugimoto N, Shigematsu T, et al. A study of second-line irinotecan plus cisplatin vs. irinotecan alone in platinum-na\u00efve patients with early relapse of gastric cancer refractory to adjuvant S-1 monotherapy: exploratory subgroup analysis of the randomized phase III TRICS trial. Cancer Chemother Pharmacol. 2019;83(5):867\u201374.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"35","key":"16587_CR20","doi-asserted-by":"publisher","first-page":"4438","DOI":"10.1200\/JCO.2012.48.5805","volume":"31","author":"S Hironaka","year":"2013","unstructured":"Hironaka S, Ueda S, Yasui H, Nishina T, Tsuda M, Tsumura T, Sugimoto N, Shimodaira H, Tokunaga S, Moriwaki T, et al. Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial. J Clin oncology: official J Am Soc Clin Oncol. 2013;31(35):4438\u201344.","journal-title":"J Clin oncology: official J Am Soc Clin Oncol"},{"issue":"4","key":"16587_CR21","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/S2468-1253(16)30219-9","volume":"2","author":"K Shitara","year":"2017","unstructured":"Shitara K, Takashima A, Fujitani K, Koeda K, Hara H, Nakayama N, Hironaka S, Nishikawa K, Makari Y, Amagai K, et al. Nab-paclitaxel versus solvent-based paclitaxel in patients with previously treated advanced gastric cancer (ABSOLUTE): an open-label, randomised, non-inferiority, phase 3 trial. lancet Gastroenterol Hepatol. 2017;2(4):277\u201387.","journal-title":"lancet Gastroenterol Hepatol"},{"issue":"1","key":"16587_CR22","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/S1470-2045(13)70549-7","volume":"15","author":"HE Ford","year":"2014","unstructured":"Ford HE, Marshall A, Bridgewater JA, Janowitz T, Coxon FY, Wadsley J, Mansoor W, Fyfe D, Madhusudan S, Middleton GW, et al. Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial. Lancet Oncol. 2014;15(1):78\u201386.","journal-title":"Lancet Oncol"},{"key":"16587_CR23","doi-asserted-by":"crossref","unstructured":"Japanese Gastric Cancer Treatment Guidelines. 2021 (6th edition). Gastric cancer: official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association. 2023;26(1):1\u201325.","DOI":"10.1007\/s10120-022-01331-8"},{"key":"16587_CR24","unstructured":"NCCN Clinical Practice Guidelines in Oncology. Gastric Cancer. Version 2.2025. https:\/\/www.nccn.org."},{"issue":"3","key":"16587_CR25","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/s11523-023-00961-x","volume":"18","author":"R Kawabata","year":"2023","unstructured":"Kawabata R, Izawa N, Suzuki T, Nagahisa Y, Nishikawa K, Takahashi M, Nakamura M, Ishiguro A, Katsuya H, Hihara J, et al. A Multicenter, Phase II Trial of Schedule Modification for Nab-Paclitaxel in Combination with Ramucirumab for Patients with Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer: The B-RAX Trial (JACCRO GC-09). Target Oncol. 2023;18(3):359\u201368.","journal-title":"Target Oncol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-16587-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16587-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16587-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T22:21:45Z","timestamp":1792707705000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-16587-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,25]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["16587"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-16587-x","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,25]]},"assertion":[{"value":"22 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the Institutional Review Board of Yamaguchi University Hospital (approval number: 2017\u2009\u2212\u2009190). The study was conducted in accordance with the Declaration of Helsinki and the Clinical Trials Act of Japan. Written informed consent was obtained from all participants before enrollment.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1273"}}